pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·53m ago·1 min read
save

Bicara appoints President Ryan Cohlhepp as CEO effective Jan. 1, while J&J veteran John Reed joins Madrigal board

Aug 14, 2026·read at Endpoints ↗Neutral

Bicara Therapeutics announced a leadership transition, naming its current President and COO Ryan Cohlhepp as the new chief executive officer effective Jan. 1.

Cohlhepp will take over the role as the company prepares for the departure of its current CEO later this year.

Separately, John Reed, a senior executive from Johnson & Johnson, has been appointed to the board of Madrigal Pharmaceuticals.

Both moves signal strategic realignments as the companies position themselves for upcoming development initiatives.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Bicara shakes up leadership ahead of CEO departure; J&J's John Reed joins Madrigal's board”

read at Endpoints ↗
91 words · retrieved 45m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Bicara Therapeutics Inc.2JOHNSON & JOHNSON

related stories

  • Jun 8J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BBioPharma Dive
  • Jun 8J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldEndpoints
  • Jun 8STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsSTAT
  • Jun 4Parabilis Medicines charts $413M IPO to back peptide pipelineEndpoints
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive